Disc Medicine, Inc. (IRON) Q3 2025 10-Q Quarterly Report
Disc Medicine, Inc. (IRON) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Disc Medicine, Inc. Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • No quarterly revenue or YoY change data disclosed in provided section
- • No profitability or margin figures presented in provided text
- • No segment or product line performance details mentioned
- • No cash position, operating cash flow, or capital deployment information provided
- • No management commentary on near-term outlook or updated guidance
Risk Factors
- • New risk: Rapid NDA filing for bitopertin in EPP and XLP in Sept 2025 with FDA's National Priority Voucher accelerates review to 1-2 months, increasing near-term regulatory pressure
- • Updated financial risk: Entered $200M senior secured Hercules Loan in Nov 2024 with maturity Dec 2029, including restrictive covenants and minimum qualified cash requirements
- • Regulatory risk: Potential FDA or TGA demands for additional preclinical studies beyond Roche data could delay marketing approvals for bitopertin
- • Operational risk: Uncertainty in completing Phase 3 and pivotal clinical trials; reliance on limited open-label Phase 2 studies raises risk to approval timelines
- • Financial risk: Cash runway extends into 2029 including 2025 public offering proceeds, but accelerating commercialization expenses for bitopertin may elevate future capital needs
Disc Medicine, Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$62M
▼ -134.3% YoY▼ -12.8% QoQ
ROE
-10.9%
Total Assets
$630M
EPS (Diluted)
$-1.78
▼ -104.6% YoY▼ -11.9% QoQ
Operating Cash Flow
-$48M
▼ -175.3% YoY▲ +0.2% QoQ
Source: XBRL data from Disc Medicine, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Disc Medicine, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.